Clinical trials: Abdominal Fat
Metabolic Syndrome, Dyslipidemia
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
The purpose of this study is to investigate if daily consumption of barley beta-glucans effect lipid and glucose metabolism and alter intestinal microbiota composition in participants with metabolic syndrome or with high risk for…
- Conditions
- Metabolic Syndrome, Dyslipidemia, Obesity, Abdominal, Hyperglycemia
- Trial name
- NCT02041104
- Testing
- Bread with added beta-glucans
- Where
- 3 sites in Slovenia
- Volunteers
- 51 people
- Sponsor
- Mlinotest Zivilska Industrija d.d.
Central Obesity, Hypertriglyceridemia
Fructose Consumption and Metabolic Dysregulation
High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD).
- Trial name
- NCT01445730
- Testing
- Fructose
- Where
- 4 sites in Canada, Finland and 2 more
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Marja-Riitta Taskinen
Fat Reduction
Non-Invasive Reduction of Abdominal Fat
This study is being performed to reduce unwanted abdominal fat using a new applicator for the Zeltiq System.
- Trial name
- JUNO (NCT01101997)
- Testing
- The Zeltiq System
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
- Trial name
- NCT00701935
- Testing
- exenatide
- Where
- 17 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Body Fat Disorder
CoolSculpting in the Abdomen Using Applicator With and Without CCI
Evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction in the abdomen using an applicator with the Crown Cooling Insert.
- Trial name
- CCI (NCT02787850)
- Testing
- CoolSculpting Treatment
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Fat Disorder
SlimShape Device for Abdominal Fat and Circumference Reduction
Prospective, one-arm, baseline-controlled, clinical study for the evaluation of the SlimShape device for non-invasive abdominal fat and circumference reduction.
- Trial name
- NCT02999763
- Testing
- SlimShape
- Where
- 4 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Obesity
Toward an Automated Method of Abdominal Fat Segmentation of MR Images
Subjects will undergo a brief magnetic resonance (MRI) scan. The resulting images will be used to compare two abdominal fat segmentation techniques. The first technique is already validated and in use.
- Trial name
- NCT01228968
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Abdominal Fat
Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction
To evaluate the safety and efficacy of the Cutera truSculpt radiofrequency device for circumferential reduction.
- Trial name
- NCT02873104
- Testing
- truSculpt rf device
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Abdominal Obesity, Growth Hormone Deficiency
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular…
- Trial name
- NCT00675506
- Testing
- Growth hormone releasing hormone (GHRH) 1-44
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Central Abdominal Bulging
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
- Trial name
- NCT02398188
- Testing
- LIPO-202
- Where
- 35 sites in United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- Evofem Inc.
Morbid Obesity
Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Excess visceral fat is a key factor in the development of metabolic syndrome associated with obesity. After bariatric surgery, patients experience weight loss accompanied by a decrease in the amount of total body fat.
- Trial name
- NCT01285791
- Where
- Israel
- Volunteers
- 39 people
- Sponsor
- Hadassah Medical Organization
Obesity, Obesity, Abdominal
Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
There is an ongoing and worsening problem with obesity in the developed, and much of the developing world. Although it has long been realized that Western diets that are rich in sugar and fat play an important role in this, it…
- Conditions
- Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
- Trial name
- VeSTAL (NCT03138369)
- Testing
- Vestibular nerve stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurovalens Ltd.
Lipodystrophy
Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference
The octipolar applicator is intended for circumference reduction treatment by reduction of adipose size and enhancement of collagen synthesis as the result thermal and non-thermal collagen stimulation.
- Trial name
- NCT02492997
- Testing
- Venus Versa, Glycerine gel
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Venus Concept
Obesity, Visceral
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in…
- Trial name
- NCT02833415
- Testing
- [U-13C3] glycerol, Empagliflozin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Obesity
Efficacy and Safety of Actiponin on Antiobesity in Obese Korean Subjects.
Obesity is a major health issue worldwide; there is a constant raise in obesity related death each year. In vitro and animal studies elucidated Actiponin as a novel anti-obesity agent.
- Trial name
- NCT01667224
- Testing
- Actiponin
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Non-Alcoholic Fatty Liver Disease, Obesity
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat
- Trial name
- NCT03375788
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Cellulite
Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body
The purpose of this study is to evaluate the Cutera radio frequency (RF) device for the new indication of reduction in size of localized areas of the body.
- Trial name
- NCT00953160
- Testing
- Cutera Radio Frequency Device
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- Cutera Inc.